Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

Cyteir Therapeutics, Inc. announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presentation at the Credit Suisse 30th Annual Healthcare Conference, being held virtually on November 8, 2021, at 4:20pm ET.

Nov. 1, 2021 11:30 UTC

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presentation at the Credit Suisse 30th Annual Healthcare Conference, being held virtually on November 8, 2021, at 4:20pm ET.

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

Contacts

INVESTOR CONTACT:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com

MEDIA CONTACT:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

MORE ON THIS TOPIC